 |
97 Diseases |  |
247 Trials |
|
247 Trials |  |
14602 News |  |
| «12...159160161162163164165166167168169170171 |
- |||||||||| Xarelto (rivaroxaban) / J&J, fondaparinux / Generic mfg.
New P3 trial: SURPRISE-2011: Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux (clinicaltrials.gov) - Dec 22, 2011
P3, N=506, Recruiting, Sponsor: GWT-TUD GmbH
- rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg.
New P4 trial: REVANT: Reversal of the Antithrombotic Action of New Oral Anticoagulants (clinicaltrials.gov) - Nov 7, 2011
P4, N=10, Recruiting, Sponsor: Gines Escolar
- ||| rivaroxaban / Generic mfg.
New P1 trial: Pharmacokinetics Study of Oral Rivaroxaban in Healthy Participants (clinicaltrials.gov) - Nov 1, 2011
P1, N=55, Completed, Sponsor: Janssen Scientific Affairs, LLC
- ||||||| rivaroxaban / Generic mfg.
Trial completion: Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study (clinicaltrials.gov) - Oct 18, 2011
P3, N=4833, Completed, Sponsor: Bayer
Active, not recruiting --> Completed
- ||||| rivaroxaban / Generic mfg.
New P2 trial: X-PLORER: Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention (clinicaltrials.gov) - Sep 27, 2011
P2, N=108, Completed, Sponsor: Bayer
- | rivaroxaban / Generic mfg.
New P1 trial: Bioequivalence Study in Healthy Subjects, 2*5 mg Tablets Rivaroxaban Versus 1*10 mg Tablet Rivaroxaban (clinicaltrials.gov) - Sep 15, 2011
P1, N=28, Completed, Sponsor: Bayer
- || Fraxiparine (nadroparin) / Aspen
New P3 trial, Surgery: DARINA: Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery (clinicaltrials.gov) - Sep 6, 2011
P3, N=150, Not yet recruiting, Sponsor: Martini Hospital Groningen
- ||||||| rivaroxaban / Generic mfg., enoxaparin sodium / Generic mfg.
Trial completion: Dose-confirmatory Bridging Study in Total Hip Replacement (clinicaltrials.gov) - Aug 8, 2011
P3, N=402, Completed, Sponsor: Bayer
Active, not recruiting --> Completed Active, not recruiting --> Completed